NO20081336L - Collagen receptor I-domain binding modulators - Google Patents
Collagen receptor I-domain binding modulatorsInfo
- Publication number
- NO20081336L NO20081336L NO20081336A NO20081336A NO20081336L NO 20081336 L NO20081336 L NO 20081336L NO 20081336 A NO20081336 A NO 20081336A NO 20081336 A NO20081336 A NO 20081336A NO 20081336 L NO20081336 L NO 20081336L
- Authority
- NO
- Norway
- Prior art keywords
- modulators
- integrin
- domain binding
- domain
- collagen receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
- C07C311/52—Y being a hetero atom
- C07C311/53—X and Y not being nitrogen atoms, e.g. N-sulfonylcarbamic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/50—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
- G01N2333/7055—Integrin beta1-subunit-containing molecules, e.g. CD29, CD49
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Abstract
Det beskrives en raffinert og detaljert molekylær modell av a2ß1-integrin-I-domenet, spesielt MIDAS, og anvendelsen av en slik modell for konstruksjon av nye integrinmodulatorer, særlig a2ß1-integrinmodulatorer. Det beskrives videre nye a a2ß1-I-domenemodulatorer som er av terapeutisk potensiale. Videre beskrives det spesifikke familier av småmolekylmodulatorer som interagerer med kollagenreseptorer, tetrasykliske polyketider og sulfonamider. Oppfinnelsen angår videre bruken av slike modulatorer for fremstillingen av medikament for trombose, inflammasjon og/eller cancer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FI20055496A FI20055496A0 (fi) | 2005-09-16 | 2005-09-16 | Kollageenireseptorien alfa-l-domeeniin sitoutuvat modulaattorit |
PCT/FI2006/050396 WO2007031608A1 (en) | 2005-09-16 | 2006-09-15 | Collagen receptor i-domain binding modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20081336L true NO20081336L (no) | 2008-06-06 |
Family
ID=35151463
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20081336A NO20081336L (no) | 2005-09-16 | 2008-03-13 | Collagen receptor I-domain binding modulators |
Country Status (13)
Country | Link |
---|---|
US (1) | US20090286713A9 (no) |
EP (1) | EP1931706A4 (no) |
JP (1) | JP2009509939A (no) |
KR (1) | KR20080067621A (no) |
CN (1) | CN101300271A (no) |
AU (1) | AU2006290621A1 (no) |
CA (1) | CA2622616A1 (no) |
FI (1) | FI20055496A0 (no) |
IL (1) | IL190130A0 (no) |
NO (1) | NO20081336L (no) |
RU (1) | RU2008114829A (no) |
WO (1) | WO2007031608A1 (no) |
ZA (1) | ZA200802510B (no) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009018623A1 (en) * | 2007-08-09 | 2009-02-12 | University Of Tasmania Through The Menzies Research Institute | Molecular markers and methods related thereto |
KR101298651B1 (ko) * | 2011-03-16 | 2013-08-21 | 연세대학교 산학협력단 | 효능이 강화된 혈관신생 억제용 약제학적 조성물 |
CN105418602B (zh) * | 2014-08-11 | 2017-01-11 | 山东国际生物科技园发展有限公司 | 一种海洋肽类化合物及其制备方法和应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4501699A (en) * | 1982-11-01 | 1985-02-26 | Litton Bionetics, Inc. | Maggiemycin, anhydromaggiemycin and processes for making |
CN100356979C (zh) * | 2000-02-03 | 2007-12-26 | 卫材R&D管理有限公司 | 整联蛋白表达抑制剂 |
WO2001073444A2 (en) * | 2000-03-28 | 2001-10-04 | Cambridge University Technical Services Limited | Receptor/peptide crystal structure for identification of inhibitors |
WO2005090297A1 (en) * | 2004-03-19 | 2005-09-29 | Biotie Therapies Corporation | Sulphonamide derivatives |
-
2005
- 2005-09-16 FI FI20055496A patent/FI20055496A0/fi not_active Application Discontinuation
-
2006
- 2006-09-15 JP JP2008530558A patent/JP2009509939A/ja active Pending
- 2006-09-15 AU AU2006290621A patent/AU2006290621A1/en not_active Abandoned
- 2006-09-15 EP EP06794113A patent/EP1931706A4/en not_active Withdrawn
- 2006-09-15 CN CNA2006800409074A patent/CN101300271A/zh active Pending
- 2006-09-15 WO PCT/FI2006/050396 patent/WO2007031608A1/en active Application Filing
- 2006-09-15 US US12/066,955 patent/US20090286713A9/en not_active Abandoned
- 2006-09-15 CA CA002622616A patent/CA2622616A1/en not_active Abandoned
- 2006-09-15 RU RU2008114829/04A patent/RU2008114829A/ru not_active Application Discontinuation
- 2006-09-15 KR KR1020087009167A patent/KR20080067621A/ko not_active Application Discontinuation
-
2008
- 2008-03-12 IL IL190130A patent/IL190130A0/en unknown
- 2008-03-13 NO NO20081336A patent/NO20081336L/no not_active Application Discontinuation
- 2008-03-14 ZA ZA200802510A patent/ZA200802510B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
US20090286713A9 (en) | 2009-11-19 |
AU2006290621A1 (en) | 2007-03-22 |
ZA200802510B (en) | 2009-01-28 |
RU2008114829A (ru) | 2009-10-27 |
US20080255028A1 (en) | 2008-10-16 |
CA2622616A1 (en) | 2007-03-22 |
EP1931706A1 (en) | 2008-06-18 |
FI20055496A0 (fi) | 2005-09-16 |
CN101300271A (zh) | 2008-11-05 |
EP1931706A4 (en) | 2009-05-27 |
KR20080067621A (ko) | 2008-07-21 |
JP2009509939A (ja) | 2009-03-12 |
WO2007031608A1 (en) | 2007-03-22 |
IL190130A0 (en) | 2008-08-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY2017029I1 (el) | ΑΝΤΙΚΑΡΚΙΝΙΚΟ ΦΑΡΜΑΚΟ ΠΟΥ ΠΕΡΙΕΧΕΙ α,α,α-ΤΡΙΦΘΟΡΟΘΥΜΙΔΙΝΗ ΚΑΙ ΑΝΑΣΤΟΛΕΑ ΦΩΣΦΟΡΥΛΑΣΗΣ ΘΥΜΙΔΙΝΗΣ | |
ECSP088508A (es) | Antagonistas de neuropilina | |
CY1114952T1 (el) | Ενεργοποιητες θειενο[2,3-b]πυριδινοδιονης της αμρκ και θεραπευτικες χρησεις αυτων | |
CL2011003085A1 (es) | Compuestos derivados de 1-(piperidin-4-il)-pirazol, moduladores de la actividad del receptor acoplado a proteina g, gpr 119; composicion farmaceutica; uso de los compuestos en el tratamiento de la diabetes o de una morbilidad asociada con dicha diabetes. | |
CY1119129T1 (el) | Ανυδρη κρυσταλλικη μορφη της διμεθοξυ ντοσεταξελης και οι διαδικασιες παρασκευης της | |
NO20091299L (no) | Substituerte sulfonamidderivater | |
ECSP099710A (es) | Derivados de piridina | |
EA201000784A1 (ru) | Антагонисты пути hedgehog и их терапевтические применения | |
CR20110245A (es) | Mutantes fgf21 y uso de los mismos. | |
NO20083891L (no) | Anti-5T4 antistoffer og anvendelser derav | |
BRPI0809583A2 (pt) | polipeptídeos fgf-21 modificados e seus usos | |
CL2011002739A1 (es) | Compuestos derivados de 3-(1h-pirrolo[2,3-b]piridina-3-carbonil)-bencenosulfonamida; composicion farmaceutica que los comprende; kit; y su uso como inhibidores de raf para el tratamiento de una enfermedad o condicion seleccionada de melanoma, glioma, glioblastoma multiforme, cancer colorrectal, cancer de pulmon, entre otras. | |
CL2009000873A1 (es) | Compuestos derivados de ciclohepta[b]piridina, antagonistas del receptor de cgrp; composicion farmaceutica; y uso para el tratamiento de la migrana.b | |
CY1111354T1 (el) | Συστασεις αναστολεα ddp iv | |
CY1112912T1 (el) | Τροποποιημενα αντισωματα αντι-ιl-23ρ19 | |
ECSP088835A (es) | Terapia combinatoria que involucra antagonistas de alfa5beta1 | |
ATE432280T1 (de) | Imidazopyridinderivate als melanocortinrezeptoragonisten | |
DK2178881T3 (da) | Hidtil ukendte 6-triazolopyridazin-sulfanyl-benzothiazol- og -benzimidazolderivater, fremgangsmåde til fremstilling deraf, anvendelse deraf som lægemidler og farmaceutiske sammensætninger og hidtil ukendt anvendelse som met-hæmmere | |
CR10160A (es) | Arildihidroisoquinolinas sustituidas con azaciclilo, procedimiento para su preparacion y su uso como medicamentos | |
CL2008002430A1 (es) | Compuestos derivados de bencenosulfonamida, inhibidores de catepsina c; composicion farmaceutica que los comprende; y su uso para el tratamiento de la epoc. | |
BRPI0517961A (pt) | piridinauréias de antranilamida como inibidores da cinase receptora do fator de crescimento endotelial vascular (vegf) | |
ECSP088691A (es) | Procesos para la síntesis convergente de los derivados de caliqueamicina | |
EA200901042A1 (ru) | Производные 1-бензенсульфонил-1h-индола в качестве ингибиторов активности ccr9 | |
DK2238110T3 (da) | 5.6-bisaryl-2-pyridin-carboxamid-derivater, fremstilling heraf og terapeutisk anvendelse heraf som urotensin II-receptorantagonister | |
CR11057A (es) | Nuevos compuestos heterociclicos nitrogenados, su preparacion y su utilizacion como medicamentos antibacterianos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |